UK researchers get 180,000 Euros to identify and develop new vaccines against Tuberculosis

NewsGuard 100/100 Score

A researcher from Birmingham University's School of Biosciences has won EU funding of 180,000 Euros to identify and develop new vaccines against Tuberculosis.

Del Besra, Professor of Microbial Physiology and Chemistry, will be looking particularly into the development of improved vaccines for the young adult population as the vast majority of TB cases seen in developing countries are in younger people.  Antibiotics will be useless in 10 or 15 years time and multi-resistant TB is becoming more prevalent in developing countries.  Courses of treatment are currently very long leading to a lack of compliance resulting in patients, who do not complete their course, remaining highly infectious so vaccination remains the most effective option.

Tuberculosis kills 3 million people every year with 30 million affected at any one time.  Areas most affected include Africa, South East Asia and South America, and outbreaks have even occurred in Britain recently. 

Professor Del Besra, lead investigator from the School of Biosciences, says, 'Our investigations will look into the use of lipids, which may prove to be invaluable for boosting the immune response to candidate vaccines in the fight against tuberculosis.'

Thirty institutions world-wide will also be working on this project including two vaccine producers and small and medium sized enterprises across Europe.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Second-line treatment for drug-resistant tuberculosis is as effective as first-line medicines